Depression Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Depression (major depressive disorder, MDD) is one of the most prevalent and disabling mental health conditions globally, affecting approximately 280 million people worldwide according to the World Health Organization. It is characterised by persistent low mood, anhedonia (inability to experience pleasure), fatigue, cognitive impairment, changes in sleep and appetite, feelings of worthlessness or guilt, and in severe cases, suicidal ideation. Depression is a clinical diagnosis made by a qualified mental health professional based on standardised criteria (DSM-5 or ICD-11), requiring symptoms to persist for at least two weeks and cause significant functional impairment.

Effective treatment of depression is multimodal, combining pharmacotherapy, psychotherapy, lifestyle interventions, and where necessary, neuromodulation or other specialist interventions. The majority of patients respond to first-line treatments — antidepressant medication and structured psychotherapy — when these are appropriately selected and adhered to. Treatment response is assessed using validated rating scales such as the Patient Health Questionnaire-9 (PHQ-9) or Hamilton Depression Rating Scale (HAMD).

Treatment is broadly structured in three phases: the acute phase (first 6–12 weeks), aimed at achieving remission of symptoms; the continuation phase (6–12 months after remission), aimed at preventing relapse; and the maintenance phase (for patients with recurrent depression or chronic illness), aimed at preventing a new depressive episode. The decision to continue or discontinue medication after the continuation phase is individualised based on the number of prior episodes, severity, and psychosocial risk factors.

Under-treatment of depression remains a global health challenge — the WHO estimates that fewer than 10% of people with depression in low-income countries receive adequate treatment. Stigma, limited access to mental health services, and misattribution of depressive symptoms to physical illness all contribute to this treatment gap. Digital mental health platforms, task-sharing models, and telepsychiatry have significantly expanded access to evidence-based care globally in recent years.

Depression treatment encompasses several distinct depressive disorders. Major depressive disorder (MDD) — the most common — is characterised by one or more major depressive episodes with complete or partial interepisode recovery. Persistent depressive disorder (dysthymia) involves chronic low-grade depressive symptoms lasting at least two years. Bipolar depression, occurring as the depressive phase of bipolar disorder, requires different pharmacological management than unipolar depression (lithium, lamotrigine, quetiapine rather than antidepressant monotherapy). Seasonal affective disorder (SAD), characterised by recurrent winter depression, responds specifically to light therapy. Postpartum depression, affecting 10–15% of new mothers, requires modified treatment protocols considering breastfeeding safety.

Treatment-resistant depression (TRD), defined as failure to achieve remission after two adequate antidepressant trials, affects approximately 30% of patients with MDD and requires specialist interventions. Secondary depression — depression occurring in the context of chronic medical illness (cancer, diabetes, cardiovascular disease, chronic pain, hypothyroidism) — is addressed through concurrent management of the underlying condition and depression-specific treatment. Depression with psychotic features, mixed features (concurrent hypomanic/manic symptoms), or comorbid personality disorder each require adjusted treatment approaches.

Any individual who meets diagnostic criteria for a depressive disorder on standardised assessment by a qualified clinician is a candidate for treatment. Initial assessment includes clinical interview, validated symptom rating scales, physical examination to exclude organic causes (thyroid dysfunction, anaemia, vitamin D deficiency, neurological conditions), and suicide risk assessment. All severity levels — mild, moderate, and severe depression — warrant active treatment, with the intensity of intervention matched to severity: guided self-help or structured exercise for mild depression; antidepressants and psychotherapy for moderate; combined pharmacotherapy, psychotherapy, and specialist care for severe; and inpatient care for patients with imminent suicide risk or inability to self-care.

Contraindications are treatment-specific rather than categorical. Antidepressants have specific contraindications — MAOIs are contraindicated with numerous medications and foods; SSRIs require caution in patients with bleeding disorders, hyponatraemia risk, or QT prolongation. Electroconvulsive therapy (ECT) has no absolute contraindications but relative caution is required in patients with elevated intracranial pressure, severe cardiac disease, or after recent myocardial infarction. Patients with bipolar disorder must not receive antidepressant monotherapy without a mood stabiliser due to the risk of inducing mania or rapid cycling.

First-line pharmacotherapy for MDD uses selective serotonin reuptake inhibitors (SSRIs: sertraline, escitalopram, fluoxetine) or serotonin-norepinephrine reuptake inhibitors (SNRIs: venlafaxine, duloxetine). These are typically initiated at low doses, titrated over 2–4 weeks, and assessed for response at 4–6 weeks. Antidepressants typically require 2–4 weeks to produce meaningful symptomatic benefit, and full response may take 6–8 weeks. Atypical antidepressants (mirtazapine, bupropion, agomelatine) offer alternative mechanisms suited to specific profiles (insomnia, sexual dysfunction concerns, weight management).

Cognitive behavioural therapy (CBT) is the most evidence-based psychotherapy for depression, with multiple Cochrane reviews confirming its efficacy equivalent to antidepressant medication for mild to moderate MDD, with superior durability (lower relapse rates) after treatment completion. Other evidence-based psychotherapies include interpersonal therapy (IPT), behavioural activation (BA), mindfulness-based cognitive therapy (MBCT — specifically recommended for relapse prevention), and problem-solving therapy. Electroconvulsive therapy (ECT) remains the most effective treatment for severe, treatment-resistant, or psychotic depression, achieving remission in 70–90% of cases. Newer neuromodulation approaches include transcranial magnetic stimulation (TMS), which is non-invasive and FDA-cleared for TRD; ketamine and esketamine (Spravato) nasal spray for rapid antidepressant effect in TRD, approved by FDA and EMA; and psilocybin-assisted therapy showing promising Phase II/III clinical trial results. The emerging role of collaborative care models — in which psychiatrists supervise and support primary care physicians in managing depression using standardised protocols, regular case reviews, and measurement-based care — has demonstrated effectiveness in increasing access to evidence-based depression treatment in resource-limited settings where specialist psychiatry capacity is insufficient to meet population need.

The majority of patients with depression — approximately 60–80% — respond to first-line antidepressant therapy or evidence-based psychotherapy when these are adequately dosed and followed for a sufficient duration. Full remission (not just response) is achieved in 30–50% of patients on first-line antidepressants, rising with sequential treatment trials. The STAR*D study, the largest antidepressant effectiveness trial conducted, showed that approximately 67% of patients achieved remission after up to four sequential treatment steps. Combination of pharmacotherapy and psychotherapy consistently outperforms either modality alone for moderate-to-severe depression in meta-analyses, with combined treatment achieving remission rates of 50–60% vs 40–50% for either alone.

Successful depression treatment produces improvements across all life domains — occupational functioning, interpersonal relationships, physical health, and quality of life. Long-term remission substantially reduces the risk of medical comorbidities associated with chronic depression, including cardiovascular disease, diabetes, dementia, and chronic pain conditions. Effective maintenance treatment reduces the risk of relapse from approximately 50% to 15–25% per year in patients with recurrent MDD. For patients with TRD responding to ECT, quality of life improvements are dramatic and often life-saving.

Antidepressant medications have a range of side effects that influence treatment adherence. SSRIs commonly cause nausea (10–30%), sexual dysfunction (up to 40%), insomnia or somnolence, and headache — most of which resolve within 2–4 weeks. Weight gain is significant with mirtazapine and paroxetine. SSRI-induced hyponatraemia (low sodium) is a serious complication particularly in elderly patients. Serotonin syndrome — potentially life-threatening — occurs from excessive serotonergic stimulation, most commonly with MAOI-SSRI combinations or co-administration with triptans or tramadol. A well-publicised FDA black box warning notes increased suicidality in patients under 25 during the first 2 weeks of antidepressant initiation — close monitoring during this period is essential.

Psychotherapy carries minimal adverse effects but is resource-intensive and may not be accessible in all settings. Transient worsening of mood or anxiety during initial CBT sessions (engaging with distressing content) is normal. ECT causes transient anterograde memory impairment in almost all patients, which typically resolves within 2–4 weeks after the treatment course. Rare risks include cardiac arrhythmia during ECT and prolonged seizure. Ketamine/esketamine can cause dissociation, elevated blood pressure, and nausea during administration — these are transient but require supervised administration in a clinical setting. Risk of psychological dependence on ketamine with repeated long-term use is a concern under investigation.

Following initiation of antidepressant therapy, patients should be reviewed at 2 weeks to assess early tolerability and at 4–6 weeks to assess treatment response. If partial response is noted at 6 weeks, a dose increase or augmentation strategy is implemented before switching agents. Once remission is achieved, continuation therapy for 6–12 months (at the same dose that achieved remission) is recommended to prevent early relapse — discontinuing antidepressants prematurely within the first year of remission carries a 50% risk of early relapse.

Patients with three or more prior depressive episodes, very severe depression, chronic depression, or significant comorbidity should be considered for long-term maintenance antidepressant therapy. Regular monitoring of metabolic parameters (weight, blood pressure, fasting glucose) is recommended for patients on atypical antipsychotics used as adjuncts. Psychotherapy sessions are typically provided weekly for 8–20 sessions, then at decreasing frequency as the patient develops skills. MBCT in 8-week group format is specifically recommended by NICE for patients with three or more prior depressive episodes as a relapse prevention strategy.

The cost of depression treatment varies substantially by modality and healthcare system. In the United States, a psychiatry consultation costs USD 200–500, with monthly follow-up at USD 150–350. Antidepressant medications on generic formularies (sertraline, fluoxetine, escitalopram) cost USD 10–30 per month; branded agents significantly more. Individual CBT with a licensed psychologist costs USD 100–300 per session; a 16-session course costs USD 1,600–4,800. TMS (36 sessions) costs USD 6,000–12,000; esketamine nasal spray USD 600–900 per session. In the United Kingdom, NHS psychiatric care and antidepressants are covered at no direct cost; waiting times vary by region. IAPT (Improving Access to Psychological Therapies) provides free CBT with typically shorter waiting times than specialist psychiatry.

Medical tourism for depression treatment is primarily relevant for psychiatric consultations and evidence-based psychotherapy at reduced costs. In India, psychiatry consultations cost USD 20–50; CBT with a trained psychologist USD 20–60 per session — savings of 70–85% vs US rates. Thailand, Turkey, and Singapore offer psychiatric services with internationally trained practitioners at significantly reduced costs. For patients with TRD requiring ketamine infusions, costs in India and Thailand are 60–70% lower than US rates. However, depression treatment usually requires ongoing contact with a local provider after returning home, limiting the scope of single-episode medical tourism.

For mild depression and as adjuncts to clinical treatment for moderate-to-severe depression, lifestyle interventions have strong evidence. Regular aerobic exercise (150 minutes weekly) has demonstrated antidepressant effects equivalent to antidepressants in mild-to-moderate depression in multiple RCTs, with additional benefits for cardiovascular health, sleep, and self-efficacy. Dietary interventions — specifically the Mediterranean diet pattern — are associated with lower depression prevalence and may have a therapeutic role. Sleep hygiene improvement is critical as insomnia and depression are bidirectionally linked; treating insomnia directly (with CBT for insomnia — CBTi) often reduces depression severity.

Light therapy (10,000 lux full-spectrum light box, 20–30 minutes in the morning) is first-line treatment for seasonal affective disorder and shows benefit in non-seasonal depression as an adjunct. Omega-3 fatty acid supplementation (EPA-dominant formulations 1–2g daily) has growing evidence as an adjunctive treatment for MDD and is generally well tolerated. St John's Wort (Hypericum perforatum) has evidence supporting efficacy equivalent to low-dose antidepressants for mild-to-moderate depression in some European studies, but significant drug interactions (with oral contraceptives, antiretrovirals, warfarin) limit its use without medical supervision. Social support interventions, peer support groups, and structured volunteering are important components of a holistic recovery plan.